TaiMed Biologics Cash Flow Conversion Efficiency
TaiMed Biologics cash flow conversion efficiency. Based on the latest financial reports, TaiMed Biologics (4147) has a cash flow conversion efficiency ratio of 0.016x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$58.88 Million ≈ $1.86 Million USD) by net assets (NT$3.68 Billion ≈ $115.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of TaiMed Biologics (2015–2025)
Cash flow conversion efficiency of TaiMed Biologics from 2015 to 2025. This chart illustrates how TaiMed Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TaiMed Biologics stock quote for real-time trading data and today's change.
TaiMed Biologics Cash Flow Conversion Ratio Explained
TaiMed Biologics cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
TaiMed Biologics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TaiMed Biologics ranked by their cash flow conversion efficiency. Also see TaiMed Biologics market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
-24.817x |
|
Beijing Comens New Materials
SHE:300200
|
-0.004x |
|
Surfilter Network Technology Co Ltd
SHE:300311
|
0.007x |
|
Guangzhou Haoyun Security Technologies Co Ltd
SHE:300448
|
-0.012x |
|
Kaiser China Holding Co Ltd
SHE:002425
|
-0.007x |
|
Oceana
JSE:OCE
|
0.157x |
|
Matrix Concepts Holdings Bhd
KLSE:5236
|
0.037x |
|
Beijing Leadman Biochemistry Co Ltd
SHE:300289
|
0.007x |
Annual Cash Flow Conversion Efficiency for TaiMed Biologics (2015–2025)
The table below shows the annual cash flow conversion efficiency of TaiMed Biologics from 2015 to 2025. Review TaiMed Biologics free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$3.86 Billion ≈ $121.54 Million |
NT$191.14 Million ≈ $6.02 Million |
0.050x | +152.52% |
| 2024-12-31 | NT$4.02 Billion ≈ $126.74 Million |
NT$-379.55 Million ≈ $-11.96 Million |
-0.094x | -845.68% |
| 2023-12-31 | NT$2.57 Billion ≈ $80.85 Million |
NT$-25.60 Million ≈ $-806.57K |
-0.010x | +95.52% |
| 2022-12-31 | NT$2.71 Billion ≈ $85.53 Million |
NT$-605.21 Million ≈ $-19.07 Million |
-0.223x | -210.36% |
| 2021-12-31 | NT$2.94 Billion ≈ $92.67 Million |
NT$-211.28 Million ≈ $-6.66 Million |
-0.072x | -21.50% |
| 2020-12-31 | NT$3.42 Billion ≈ $107.62 Million |
NT$-201.94 Million ≈ $-6.36 Million |
-0.059x | +67.65% |
| 2019-12-31 | NT$3.59 Billion ≈ $112.99 Million |
NT$-655.31 Million ≈ $-20.65 Million |
-0.183x | -42.60% |
| 2018-12-31 | NT$4.08 Billion ≈ $128.56 Million |
NT$-522.86 Million ≈ $-16.47 Million |
-0.128x | -6.49% |
| 2017-12-31 | NT$4.29 Billion ≈ $135.23 Million |
NT$-516.48 Million ≈ $-16.27 Million |
-0.120x | -229.21% |
| 2016-12-31 | NT$4.71 Billion ≈ $148.51 Million |
NT$-172.29 Million ≈ $-5.43 Million |
-0.037x | +59.87% |
| 2015-12-31 | NT$4.90 Billion ≈ $154.37 Million |
NT$-446.26 Million ≈ $-14.06 Million |
-0.091x | -- |
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more